Sky Century Investment, Inc. (SKYI)
OTCMKTS · Delayed Price · Currency is USD
0.0055
0.00 (0.00%)
Jan 20, 2026, 4:00 PM EST
Sky Century Investment Revenue
Sky Century Investment had revenue of $13.15K in the quarter ending November 30, 2025. This brings the company's revenue in the last twelve months to $89.49K, up 164.37% year-over-year. In the fiscal year ending August 31, 2025, Sky Century Investment had annual revenue of $76.34K with 47.37% growth.
Revenue (ttm)
89.49K
Revenue Growth
+164.37%
P/S Ratio
13.74
Revenue / Employee
89.49K
Employees
1
Market Cap
1.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 76.34K | 24.54K | 47.37% |
| Aug 31, 2024 | 51.80K | -17.96K | -25.75% |
| Aug 31, 2023 | 69.76K | -5.00K | -6.69% |
| May 31, 2023 | 74.76K | 13.76K | 22.56% |
| May 31, 2022 | 61.00K | - | - |
| May 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |